ReSPECT-GBM Clinical Trial: Advancing Treatment for Recurrent Glioblastoma (GBM)
Glioblastoma (GBM) is one of the most aggressive and treatment-resistant brain cancers, with limited therapeutic options available for patients with recurrent disease. The ReSPECT-GBM clinical trial is evaluating an innovative, targeted radiotherapeutic designed to improve outcomes for patients with recurrent GBM.
About the ReSPECT-GBM Trial
The trial is studying Rhenium (186Re) Obisbemeda, a novel precision radiotherapy that delivers high-dose radiation directly to the tumor while minimizing exposure to surrounding healthy tissue.
Key Benefits of Rhenium (186Re) Obisbemeda
- Targeted Therapy: Administered directly into the tumor site for maximum impact
- Minimally Invasive: Uses convection-enhanced delivery (CED) for precise treatment
- Potential to Improve Survival: Phase 1 results show promising safety and efficacy
📢 Now Enrolling Eligible Patients
The ReSPECT-GBM trial is actively recruiting patients diagnosed with recurrent glioblastoma. Physicians and clinical sites interested in participation are also encouraged to inquire.
📍 Learn more & apply for the trial:
🔗 ReSPECT-GBM Clinical Trial
Stay informed about cutting-edge GBM treatments and the latest breakthroughs in radiotherapeutics.
#Glioblastoma #GBM #BrainCancer #ClinicalTrials #Oncology #NeuroOncology #CancerResearch #Radiotherapy #MedicalInnovation
Recent Comments